跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 2,324 条关于
“NBI-1140675”
全部
2,324
临床试验
1,581
药物
569
机构
17
资讯
157
去年
Neurocrine Launches Phase 1 Trial of Novel VMAT2 Inhibitor for Neurological Disorders
23天前
FDA Clears IND for Neurocrine and Nxera's Oral M1 Agonist NBI-1117567 in Alzheimer's Cognition
10个月前
Neurocrine's NBI-1070770 Fails to Meet Primary Endpoint in Phase II Major Depressive Disorder Trial
2年前
Neurocrine's NBI-1117568 Shows Promise in Phase II Schizophrenia Trial
2年前
Nxera Pharma Secures $35M Milestone Payment After Positive Phase II Schizophrenia Trial
去年
Neurocrine Biosciences Advances Novel Muscarinic M4 Agonist to Phase 3 Trials for Schizophrenia
2年前
FDA Grants Breakthrough Therapy Designation to Crinecerfont for Congenital Adrenal Hyperplasia
9个月前
Neurocrine Biosciences Initiates Phase 2a Trial for Schizophrenia Treatment Following Depression Drug Setback
去年
Altimmune and MindMed Join Nasdaq Biotechnology Index, Anticipate Key Clinical Data in 2025
2年前
Neurocrine's Luvadaxistat Fails Phase II Trial for Cognitive Impairment in Schizophrenia
第 1 页,共 16 页
上一页
下一页